Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features

PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer

(2020) Gianluca Lopez et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide

(2020) Nobuhiro Hata et al.   JOURNAL OF NEURO-ONCOLOGY

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

(2020) Sue Han et al.   BRITISH JOURNAL OF CANCER

FBXO22 degrades nuclear PTEN to promote tumorigenesis

(2020) Meng-Kai Ge et al.   Nature Communications

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

(2020) David A. Reardon et al.   JAMA Oncology

Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma

(2020) Kristen A Batich et al.   CLINICAL CANCER RESEARCH

Molecular responses to immune checkpoint blockade in glioblastoma

(2019) Hirotaka Ito et al.   NATURE MEDICINE

PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma

(2019) Yong Jae Shin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

(2019) Xin Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

PTEN reduces endosomal PtdIns(4,5)P2 in a phosphatase-independent manner via a PLC pathway

(2019) Virginie E. Mondin et al.   JOURNAL OF CELL BIOLOGY

Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness

(2019) Siti Farah Bte Fadhlullah et al.   ONCOGENE

A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872

(2019) Evanthia Galanis et al.   CANCER

Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma

(2019) Peiwen Chen et al.   CANCER CELL

Autophagy: Supporting cellular and organismal homeostasis by self-eating

(2019) Eeva-Liisa Eskelinen   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

(2019) Anand Rotte   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players

(2019) Xiaotian Yuan et al.   ONCOGENE

PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1

(2019) Xu Qian et al.   MOLECULAR CELL

Toward understanding the origin and evolution of cellular organisms

(2019) Minoru Kanehisa   PROTEIN SCIENCE

Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets

(2019) Olivia G. Taylor et al.   Frontiers in Oncology

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)

(2019) John D. Hainsworth et al.   JOURNAL OF NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

(2019) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Personalized neoantigen vaccines: A new approach to cancer immunotherapy

(2018) Amanda R. Aldous et al.   BIOORGANIC & MEDICINAL CHEMISTRY

TP53 gain-of-function mutation promotes inflammation in glioblastoma

(2018) Seok Won Ham et al.   CELL DEATH AND DIFFERENTIATION

The perfect personalized cancer therapy: cancer vaccines against neoantigens

(2018) Luigi Aurisicchio et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Wild-type and mutated IDH1/2 enzymes and therapy responses

(2018) Remco J. Molenaar et al.   ONCOGENE

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

(2018) Shabierjiang JIAPAER et al.   NEUROLOGIA MEDICO-CHIRURGICA

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma

(2018) Xiaoyue Chen et al.   Nature Communications

Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR–CHK1, p21, and NF-κB

(2018) Dorthe Aasland et al.   CANCER RESEARCH

ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma

(2018) Qian Chen et al.   JOURNAL OF PATHOLOGY

Actively personalized vaccination trial for newly diagnosed glioblastoma

(2018) Norbert Hilf et al.   NATURE

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

New approach for understanding genome variations in KEGG

(2018) Minoru Kanehisa et al.   NUCLEIC ACIDS RESEARCH

Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas

(2017) C. J. Herting et al.   GLIA

PTEN drives Th17 cell differentiation by preventing IL-2 production

(2017) Hyeong Su Kim et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Systematic analysis of telomere length and somatic alterations in 31 cancer types

(2017) Floris P Barthel et al.   NATURE GENETICS

Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype

(2017) Jian Teng et al.   NEURO-ONCOLOGY

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

(2017) Antonio Omuro et al.   NEURO-ONCOLOGY

Direct electrical bipolar electrostimulation for functional cortical and subcortical cerebral mapping in awake craniotomy. Practical considerations

(2017) J. Pallud et al.   NEUROCHIRURGIE

Strategies of temozolomide in future glioblastoma treatment

(2017) Chooi Yeng Lee   OncoTargets and Therapy

PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3

(2017) Jorge A. Benitez et al.   Nature Communications

Lactate Dehydrogenase C Produces S-2-Hydroxyglutarate in Mouse Testis

(2016) Xin Teng et al.   ACS Chemical Biology

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

IDH mutations in cancer and progress toward development of targeted therapeutics

(2016) L. Dang et al.   ANNALS OF ONCOLOGY

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma

(2016) X. Lun et al.   CLINICAL CANCER RESEARCH

Isocitrate Dehydrogenase Mutation Leads to Alteration in 3-Dimensional DNA Structure and Oncogene Activation in Gliomas

(2016) Robert M. Starke et al.   NEUROSURGERY

Toward a Shared Vision for Cancer Genomic Data

(2016) Robert L. Grossman et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis

(2016) Hua Yang et al.   OncoTargets and Therapy

EMC6/TMEM93 suppresses glioblastoma proliferation by modulating autophagy

(2016) X Shen et al.   Cell Death & Disease

Temozolomide Nanoparticles for Targeted Glioblastoma Therapy

(2015) Chen Fang et al.   ACS Applied Materials & Interfaces

Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes

(2015) Sheila R. Alcantara Llaguno et al.   CANCER CELL

Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide

(2015) S. F. Murphy et al.   CANCER RESEARCH

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Autophagy in stress and disease

(2015) M Chiara Maiuri et al.   CELL DEATH AND DIFFERENTIATION

Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis

(2015) Xiaogang Wang et al.   MOLECULAR NEUROBIOLOGY

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

(2015) Duane A. Mitchell et al.   NATURE

Insulator dysfunction and oncogene activation in IDH mutant gliomas

(2015) William A. Flavahan et al.   NATURE

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

IDH1/2 mutation detection in gliomas

(2014) Hideyuki Arita et al.   Brain Tumor Pathology

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Current Concepts in the Surgical Management of Glioma Patients

(2014) C. Watts et al.   CLINICAL ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Visualizing Molecular Profiles of Glioblastoma with GBM-BioDP

(2014) Orieta Celiku et al.   PLoS One

ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

(2014) S. Agnihotri et al.   Cancer Discovery

IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma

(2014) Yong-Gang Yao   MEDICAL SCIENCE MONITOR

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study

(2013) Pedro Castelo-Branco et al.   LANCET ONCOLOGY

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma

(2013) Chunzhi Zhang et al.   NEURO-ONCOLOGY

Angiogenesis in Glioblastoma

(2013) Sunit Das et al.   NEW ENGLAND JOURNAL OF MEDICINE

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Highly Recurrent TERT Promoter Mutations in Human Melanoma

(2013) F. W. Huang et al.   SCIENCE

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

(2013) S. J. Klempner et al.   Cancer Discovery

Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines

(2013) N. Hacohen et al.   Cancer Immunology Research

Mammalian Phospholipase C

(2012) Ganesh Kadamur et al.   Annual Review of Physiology

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Telomeres—structure, function, and regulation

(2012) Weisi Lu et al.   EXPERIMENTAL CELL RESEARCH

Impact of Intraoperative Stimulation Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis

(2012) Philip C. De Witt Hamer et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway

(2012) Chenli Lin et al.   NEUROSCIENCE LETTERS

Antiangiogenic Therapy for Cancer: An Update

(2012) Belal Al-Husein et al.   PHARMACOTHERAPY

Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of NAD+ Biosynthesis and Base Excision Repair

(2011) E. M. Goellner et al.   CANCER RESEARCH

An extent of resection threshold for newly diagnosed glioblastomas

(2011) Nader Sanai et al.   JOURNAL OF NEUROSURGERY

Transdifferentiation of glioblastoma cells into vascular endothelial cells

(2011) Y. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

MGMT-Independent Temozolomide Resistance in Pediatric Glioblastoma Cells Associated with a PI3-Kinase-Mediated HOX/Stem Cell Gene Signature

(2010) N. Gaspar et al.   CANCER RESEARCH

HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors

(2010) N. Ahmed et al.   CLINICAL CANCER RESEARCH

Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA

(2010) Walter Stummer et al.   JOURNAL OF NEURO-ONCOLOGY

Glioblastoma stem-like cells give rise to tumour endothelium

(2010) Rong Wang et al.   NATURE

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function

(2010) David Warde-Farley et al.   NUCLEIC ACIDS RESEARCH

The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation

(2009) J. Portnow et al.   CLINICAL CANCER RESEARCH

Decreased expression of neurofibromin contributes to epithelial-mesenchymal transition in neurofibromatosis type 1

(2009) Yoshimi Arima et al.   EXPERIMENTAL DERMATOLOGY

The EGFRvIII variant in glioblastoma multiforme

(2009) Hui K. Gan et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

(2009) Jennifer A. Quinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytoplasmic functions of the tumour suppressor p53

(2009) Douglas R. Green et al.   NATURE

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis

(2009) Giulia Fontemaggi et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Tumor Suppressive Functions of p53

(2009) J. T. Zilfou et al.   Cold Spring Harbor Perspectives in Biology

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

(2008) David A Reardon et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Transcriptional control of human p53-regulated genes

(2008) Todd Riley et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cytomegalovirus Immunity after Vaccination with Autologous Glioblastoma Lysate

(2008) Robert M. Prins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE